Table 1 Clinical characteristics of the total UC patient series
From: Efficacy and safety of tacrolimus in older adults with ulcerative colitis: a retrospective study
Younger (< 65 yrs. old) n = 116 | Elderly (≥65 yrs. old) n = 21 | p-value | |
|---|---|---|---|
Gender, male:female | 76:40 | 9:12 | 0.052 |
Age (yrs) | 39.4 ± 11.7 | 68.9 ± 6.2 | < 0.0001 |
Age at onset (yrs) | 32 ± 12.6 | 59.8 ± 11.6 | < 0.0001 |
Duration of disease | 7.9 ± 7.6 | 9.4 ± 10.1 | 0.923 |
Site involved left-sided colitis/total colitis | 31 / 85 | 3 /18 | 0.202 |
Concomitant drugs: | |||
5-ASA | 102 (87.9%) | 14 (66.7%) | 0.022 |
PSL | 111 (95.6%) | 18 (85.7%) | 0.072 |
Immunomodulator | 33 (28.4%) | 6 (28.5%) | 0.99 |
Biological | 37 (31.9%) | 3 (14.2%) | 0.102 |
Admission date: | |||
CAI on admission | 13.0 ± 2.8 | 13.2 ± 2.8 | 0.754 |
Hb on admission (g/dl) | 12.2 ± 2.2 | 11.3 ± 1.4 | 0.035 |
Alb on admission (g/dl) | 3.4 ± 0.6 | 3.0 ± 0.5 | 0.012 |
CRP on admission (mg/dl) | 3.9 ± 5.6 | 5.0 ± 5.8 | 0.035 |
eGFR on admission (ml/min) | 89.8 ± 23.5 | 64.7 ± 14.7 | < 0.001 |
Cr on admission (ml/min) | 0.82 ± 0.8 | 0.8 ± 0.1 | 0.266 |
Mayo score on admission | 2.8 ± 0.3 | 2.9 ± 0.2 | 0.3873 |
UCEIS score on admission | 6.4 ± 1.1 | 6.7 ± 0.9 | 0.3704 |
Time to reach target TAC trough (days) | 2.7 ± 1.9 | 3.2 ± 2.5 | 0.5879 |
Length of hospital stay (day) | 32.8 ± 12.6 | 30.7 ± 12.7 | 0.7335 |
Concomitant disease:ayes | 37 | 56 | < 0.0001 |
Cardiovascular disease (atrial fibrillation/ cardiomyopathy/ hypertension) | 4 (0 / 0 / 3) | 8 (2 / 0 / 8) | < 0.0001 |
Gastrointestinal disease (gastric ulcer) | 0 | 1 | 0.0183 |
Liver disease (hepatitis B/ hepatitis C, fatty liver/ PSC) | 5 (0/1/3/1) | 2 (1/0/1/0) | 0.26 |
Pulmonary disease (Asthma,Asthma and COPD Overlap,pneumocystis pneumonia/ interstitial pneumonia) | 2 (1 / 0 / 0 / 1 / 0) | 4 (1 / 1 / 0 / 0 / 2) | 0.0033 |
Renal disease (Interstitial Nephritis/Renal Transplantation/Diabetic Kidney Disease) | 2 (1 / 1 / 0) | 1 (0 / 0 / 1) | 0.3814 |
Neurological disease (cerebral infarction/ Parkinson disease/brain artery) | 2 (0 / 0 / 2) | 3 (1 / 1 / 1) | 0.0191 |
Mental illness (bipolar disorder/ depression/ insomnia) | 8 (0/3/5) | 8 (1 / 2 / 3) | 0.0018 |
Metabolic diseasea (thyroid disease, hyperlipidemia/ hyperuricemia, diabetes) | 5 (0/ 5 / 0 / 0) | 7 (3/ 2 / 1 / 1) | < 0.0001 |
Orthopedic disease (osteoporosis/ cervical disc herniation/ spinal canal stenosis) | 5 (5 / 0 / 0) | 10 (5 / 2 / 3) | 0.04 |
Autoimmune disease (rheumatoid arthritis/ Hashimoto disease/ Takayasu’s disease, systemic lupus erythematosus) | 2 (0/ 0 / 1 / 1) | 3 (1/ 1 / 1 / 0) | 0.0191 |
Ophthalmologic disease (glaucoma/ cataract) | 2 (0 / 2) | 5 (2 / 3) | 0.0005 |
Cancer (Uterine cancer Renal cancer Prostate cancer) | 0 | 4 (1 / 1 / 1 / 1) | < 0.0001 |
CCI | 0.42 ± 0.74 | 1.76 ± 0.94 | < 0.0001 |